A double-blinded placebo-controlled pilot trial of calcium alumina-silicate (CASAD) in the treatment of severe diarrhea (grade 3 or 4) in cancer patients presenting for emergency care.

Trial Profile

A double-blinded placebo-controlled pilot trial of calcium alumina-silicate (CASAD) in the treatment of severe diarrhea (grade 3 or 4) in cancer patients presenting for emergency care.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Calcium aluminium silicate (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Dec 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT02018653).
    • 20 Dec 2013 Planned end date 1 Dec 2015 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top